Published in Lancet on June 12, 1999
Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure (PREVALENT) | NCT03644446
A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell (2008) 6.16
A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med (2008) 3.98
Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol (2006) 3.20
Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol (2009) 2.14
Disease management programme for secondary prevention of coronary heart disease and heart failure in primary care: a cluster randomised controlled trial. Heart (2007) 1.91
Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med (2008) 1.88
Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail (2009) 1.78
Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure. Circ Arrhythm Electrophysiol (2011) 1.56
Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail (2012) 1.55
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J (2016) 1.54
Benefit of beta-blockers for heart failure: proven in 1999. Lancet (1999) 1.53
Local β-adrenergic stimulation overcomes source-sink mismatch to generate focal arrhythmia. Circ Res (2012) 1.53
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc (2010) 1.51
Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women. J Gerontol A Biol Sci Med Sci (2012) 1.50
Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J (2013) 1.49
Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study. Eur Heart J (2015) 1.49
Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail (2015) 1.48
Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation (2008) 1.44
Sudden cardiac death in patients with human immunodeficiency virus infection. J Am Coll Cardiol (2012) 1.44
Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol (2009) 1.42
Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol (2011) 1.42
Mechanisms of altered Ca²⁺ handling in heart failure. Circ Res (2013) 1.37
Beta blockers in hypertension and cardiovascular disease. BMJ (2007) 1.37
Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest (2001) 1.37
Cardiac innervation and sudden cardiac death. Circ Res (2015) 1.29
Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart (2005) 1.29
Prediction and prevention of sudden cardiac death in heart failure. Heart (2005) 1.29
Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol (2012) 1.29
Arrhythmogenic effects of beta2-adrenergic stimulation in the failing heart are attributable to enhanced sarcoplasmic reticulum Ca load. Circ Res (2008) 1.25
Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail (2009) 1.25
[Guidelines for therapy of chronic heart failure]. Z Kardiol (2005) 1.24
Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. BMJ (2002) 1.22
CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol (2012) 1.20
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail (2011) 1.20
A common genetic variant within SCN10A modulates cardiac SCN5A expression. J Clin Invest (2014) 1.17
New therapeutic targets in cardiology: arrhythmias and Ca2+/calmodulin-dependent kinase II (CaMKII). Circulation (2012) 1.16
Cardiomyopathy, familial dilated. Orphanet J Rare Dis (2006) 1.14
NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart (2003) 1.13
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. Eur J Heart Fail (2010) 1.12
Risk stratification for sudden cardiac death: current status and challenges for the future. Eur Heart J (2014) 1.11
Endothelial nitric oxide synthase decreases beta-adrenergic responsiveness via inhibition of the L-type Ca2+ current. Am J Physiol Heart Circ Physiol (2008) 1.11
Maximum potential benefit of implantable defibrillators in preventing sudden death after hospital admission because of heart failure. CMAJ (2009) 1.10
β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin (2012) 1.10
Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. Am J Kidney Dis (2011) 1.09
Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol (2000) 1.07
Characteristics, management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers: results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry. Clin Res Cardiol (2014) 1.04
'Integrative Physiology 2.0': integration of systems biology into physiology and its application to cardiovascular homeostasis. J Physiol (2011) 1.01
Junctin and the histidine-rich Ca2+ binding protein: potential roles in heart failure and arrhythmogenesis. J Physiol (2009) 1.01
Mechanisms of disease: detrimental adrenergic signaling in acute decompensated heart failure. Nat Clin Pract Cardiovasc Med (2008) 1.00
Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med (2011) 1.00
Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Mol Pharmacol (2009) 1.00
Beta-blocker use for the stages of heart failure. Mayo Clin Proc (2009) 1.00
Effects of renal sympathetic denervation on post-myocardial infarction cardiac remodeling in rats. PLoS One (2012) 0.99
Epidemiological trends in invasive mechanical ventilation in the United States: A population-based study. J Crit Care (2015) 0.98
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. Heart (2003) 0.98
Diastolic dysfunction and atrial fibrillation. J Interv Card Electrophysiol (2008) 0.98
Measurement of sympathetic nervous system activity in heart failure: the role of norepinephrine kinetics. Heart Fail Rev (2000) 0.97
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci (2011) 0.97
Predicting sudden death in patients with mild to moderate chronic heart failure. Heart (2004) 0.97
Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev (2013) 0.96
Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts. Pflugers Arch (2004) 0.96
Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis. Heart Fail Rev (2012) 0.96
Brief report: beta-blocker use among veterans with systolic heart failure. J Gen Intern Med (2006) 0.96
Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther (2009) 0.96
Gender and heart failure: a population perspective. Heart (2006) 0.96
Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol (2001) 0.96
Management of heart failure in the elderly. Heart Fail Rev (2002) 0.96
Wenxin-Keli Regulates the Calcium/Calmodulin-Dependent Protein Kinase II Signal Transduction Pathway and Inhibits Cardiac Arrhythmia in Rats with Myocardial Infarction. Evid Based Complement Alternat Med (2013) 0.95
Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts. J Am Heart Assoc (2013) 0.95
Shorter difference between myocardium and blood optimal inversion time suggests diffuse fibrosis in dilated cardiomyopathy. J Magn Reson Imaging (2009) 0.95
Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol (2010) 0.94
Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. PLoS One (2012) 0.94
β-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One (2011) 0.93
Nebivolol in the treatment of chronic heart failure. Vasc Health Risk Manag (2007) 0.93
Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev (2004) 0.93
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol (2012) 0.92
Remodeling of calcium handling in human heart failure. Adv Exp Med Biol (2012) 0.91
β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord (2013) 0.90
Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients. Br J Clin Pharmacol (2011) 0.90
Cost-effectiveness of heart failure therapies. Nat Rev Cardiol (2013) 0.89
The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure. Heart Fail Rev (2012) 0.89
Does modern medicine increase life-expectancy: Quest for the Moon Rabbit? Indian Heart J (2016) 0.89
The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy. Clinics (Sao Paulo) (2012) 0.89
Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol (2013) 0.89
Beta blockers in older persons with heart failure: tolerability and impact on quality of life. Heart (2002) 0.89
Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial. BMC Geriatr (2012) 0.88
Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol (2012) 0.88
Rationale and study design of a cross sectional study documenting the prevalence of Heart Failure amongst the minority ethnic communities in the UK: the E-ECHOES Study (Ethnic--Echocardiographic Heart of England Screening Study). BMC Cardiovasc Disord (2009) 0.87
Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis. J Interv Card Electrophysiol (2011) 0.87
Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease. Heart Fail Clin (2012) 0.87